Pharmacologic Vitreolysis with Ocriplasmin: Rationale for Use and Therapeutic Potential in Vitreo-Retinal Disorders
Abstract
With increased knowledge about the origins and pathophysiology of vitreo-retinal disorders—and, in particular, the central role of anomalous posterior vitreous detachment in vitreo-maculopathies—a paradigm shift from surgery to pharmacotherapy is taking place with the development of pharmacologic vitreolysis. The first approved agent for pharmacologic vitreolysis therapy is ocriplasmin, a truncated form of the nonspecific serine protease...
Paper Details
Title
Pharmacologic Vitreolysis with Ocriplasmin: Rationale for Use and Therapeutic Potential in Vitreo-Retinal Disorders
Published Date
Mar 27, 2015
Journal
Volume
29
Issue
2
Pages
103 - 112
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History